Stephen A Sands1,2, Brian T Harel3,4, Mirko Savone5, Kara Kelly5, Veena Vijayanathan6, Jennifer Greene Welch7, Lynda Vrooman8, Lewis B Silverman8, Peter D Cole6. 1. Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, USA. sandss@mskcc.org. 2. Division of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue 7th Floor, New York, NY, 10022, USA. sandss@mskcc.org. 3. Cogstate, Inc., 195 Church Street, New Haven, CT, USA. 4. Yale School of Medicine, Yale Child Study Center, 230 South Frontage Rd, New Haven, CT, USA. 5. Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, USA. 6. Department of Pediatrics, Albert Einstein College of Medicine, 3415 Bainbridge Avenue, Bronx, NY, USA. 7. Division of Pediatric Hematology/Oncology, Department of Pediatrics, Alpert Medical School of Brown University, Providence, RI, USA. 8. Department of Pediatric Oncology, Dana-Farber Cancer Institute/Division of Pediatric Hematology-Oncology, Boston Children's Hospital, 450 Brookline Avenue, Boston, MA, USA.
Abstract
PURPOSE:Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. METHODS: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. RESULTS: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. CONCLUSIONS: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.
RCT Entities:
PURPOSE:Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. METHODS: This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. RESULTS: Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects (N = 34) completed Cogstate baseline testing, while completion and performance checks indicate that 100 % of subjects completed testing and complied with test requirements. The majority (85 %) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. CONCLUSIONS: The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.
Entities:
Keywords:
Acute lymphoblastic leukemia; Biomarkers; Late effects; Methotrexate; Neurocognitive; Neurotoxicity
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Cancer Date: 2006-05-01 Impact factor: 6.860
Authors: Annemieke I Buizer; Leo M J de Sonneville; Marry M van den Heuvel-Eibrink; Anjo J P Veerman Journal: Pediatr Blood Cancer Date: 2005-09 Impact factor: 3.167
Authors: Peter D Cole; Katherine A Beckwith; Veena Vijayanathan; Sudipta Roychowdhury; Angela K Smith; Barton A Kamen Journal: Pediatr Neurol Date: 2009-01 Impact factor: 3.372
Authors: Wanda L Salzer; Michael J Burke; Meenakshi Devidas; Yunfeng Dai; Kristina K Hardy; John A Kairalla; Lia Gore; Joanne M Hilden; Eric Larsen; Karen R Rabin; Patrick A Zweidler-McKay; Michael J Borowitz; Brent Wood; Nyla A Heerema; Andrew J Carroll; Naomi Winick; William L Carroll; Elizabeth A Raetz; Mignon L Loh; Stephen P Hunger Journal: J Clin Oncol Date: 2020-06-04 Impact factor: 44.544
Authors: Amy M Berkman; Karly M Murphy; Elizabeth J Siembida; Nancy Lau; Yimin Geng; Susan K Parsons; John M Salsman; Michael E Roth Journal: Value Health Date: 2021-08-08 Impact factor: 5.725
Authors: Andrew M Heitzer; Jason M Ashford; Brian T Harel; Adrian Schembri; Michelle A Swain; Joanna Wallace; Kirsten K Ness; Fang Wang; Hui Zhang; Thomas E Merchant; Giles W Robinson; Amar Gajjar; Heather M Conklin Journal: J Neurooncol Date: 2018-11-22 Impact factor: 4.130
Authors: Margaret T Davis; Nicole DellaGiogia; Paul Maruff; Robert H Pietrzak; Irina Esterlis Journal: Transl Psychiatry Date: 2021-04-08 Impact factor: 6.222
Authors: Irina Esterlis; Sarah DeBonee; Ryan Cool; Sophie Holmes; Stephen R Baldassari; Paul Maruff; Robert H Pietrzak; Margaret T Davis Journal: Chronic Stress (Thousand Oaks) Date: 2022-08-04
Authors: Marita Partanen; Sean Phipps; Kathryn Russell; Doralina L Anghelescu; Joshua Wolf; Heather M Conklin; Kevin R Krull; Hiroto Inaba; Ching-Hon Pui; Lisa M Jacola Journal: J Pediatr Psychol Date: 2021-02-19